Name: Relias Media
Price range: $

Addition of Ezetimibe to Simvastatin May Improve CV Outcomes

A new study suggests the addition of ezetimibe to simvastatin may improve cardiovascular outcomes in patients with acute coronary syndrome, although the effect is modest.

Beta-blockade Use in Non-cardiac Surgery Patients

Perioperative beta-blockade appears to be beneficial for patients with high cardiac risk factors undergoing NCS, but it increased the risk of death in those with no cardiac risk factors.

FDA Actions

The FDA has approved the first spray-dried fibrin sealant to help control bleeding during surgery.

Treating CDI with Fecal Microbiota Transplantation

Recurrent Clostridium difficile infection (CDI) is defined as the recurrence of infection after successful initial therapy.

Low Molecular Weight Heparin and RPL

The common practice of giving daily low molecular weight heparin to women to prevent recurrent pregnancy loss may not be an effective intervention, according to a new study.

Ramelteon May Be Effective for Treating Delirium

According to the findings of a new study, Ramelteon may be effective for treating delirium in older hospitalized patients.

No Link Between MMR and Autism

In this issue: Prevention of Type 1 Diabetes in Children; Early Initiation of HPV Vaccine; Effects of Antibiotic Exposure Early in Life; ED-initiated Buprenorphine for Opioid-dependent Patients; and FDA Actions.

FDA Greenlights Biosimilars

In one of the most important decisions of the past 5 years, the FDA has given the greenlight to the first biosimilar drug with the approval of Sandoz’s filgrastim-sndz, a copy of Amgen’s multibillion dollar drug filgrastim (Neupogen). Biosimilars are drugs that are derived from living organisms and thus cannot be exact copies of the original compounds. They are different from generics in this respect. But the FDA has agreed to approve biologic copies that are “highly similar to another, already FDA-approved biologic (known as the reference product).”